Page last updated: 2024-09-05

re 102 and Thrombocythemia, Essential

re 102 has been researched along with Thrombocythemia, Essential in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Atsuta, Y; Doki, N; Fukuda, T; Ichinohe, T; Ishikawa, J; Kanda, Y; Kiyoi, H; Minami, Y; Mori, T; Murata, M; Nagamura-Inoue, T; Nishida, T; Shimazu, Y; Shirane, S; Suzuki, R; Tanaka, M; Togitani, K; Uchida, N	1

Other Studies

1 other study(ies) available for re 102 and Thrombocythemia, Essential

Article	Year
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis. Internal medicine (Tokyo, Japan), 2020, Volume: 59, Issue:16 Topics: Adult; Aged; Erythrocyte Transfusion; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Morpholines; Platelet Transfusion; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Retrospective Studies; Survival Rate; Thrombocythemia, Essential; Tissue Donors; Transplantation, Homologous; Treatment Outcome	2020

Article

Year

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.

Internal medicine (Tokyo, Japan), 2020, Volume: 59, Issue:16

Topics: Adult; Aged; Erythrocyte Transfusion; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Morpholines; Platelet Transfusion; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Retrospective Studies; Survival Rate; Thrombocythemia, Essential; Tissue Donors; Transplantation, Homologous; Treatment Outcome

2020